

# Original Research Article

**Multi-drug resistance pattern of *Staphylococcus aureus* from Paediatric ward, General Hospital, Ikot-Ekpaw, Mkpato Enin LGA, Akwa-Ibom State, Nigeria.**

## **ABSTRACT**

**AIM:** This study evaluated the Multi-drug resistance (MDR) pattern of *Staphylococcus aureus* from a paediatric ward and was conducted using standard clinical microbiological procedures.

**LOCATION AND DURATION OF STUDY:** The study was carried out on infant samples collected from the Paediatric ward, General Hospital, Ikot-Ekpaw, Mkpato Enin LGA, Akwa-Ibom State, Nigeria, over three (3) months period.

**DESIGN OF STUDY:** Hundred swab-samples were inoculated on Mannitol salt agar. Positive growths were further biochemically confirmed for *Staphylococcus aureus*. Confirmed isolates were then used for MDR evaluation.

**RESULT AND INTERPRETATION:** Of the 100 samples from skin, wound, ear, throat and nose swabs, 28 isolates were confirmed as *S. aureus* and were subjected to a range of selected commercially available antibiotics like: amoxicillin, ampiclox, chloramphenicol, ciprofloxacin, erythromycin, gentamicin, levofloxacin, norfloxacin, rifampicin and streptomycin, to evaluate their susceptibilities. The wound swabs gave the highest isolate percentage yield (32%) followed by skin swabs (29%). Susceptibility results showed that amoxicillin and ampiclox were more resisted by the isolates, while ciprofloxacin, levofloxacin and norfloxacin were more effective against the isolates. The Multiple antibiotics resistance (MAR) indices showed that 85.7% of the isolates had confirmed multi-drug resistance status, with 60.7% of the isolates having resistance for between four or more the tested antimicrobials. MAR indices revealed that 96.4% of the isolates had 0.3, indicating that the resistance resulted from isolates that adapted to the tested drugs due to some form of abuse. Restricted use of these drugs would help curtail the high resistance currently experienced amongst microorganisms.

Key words: multi-drug resistance, *Staphylococcus aureus*, multiple antibiotics resistance index, susceptibility test, nosocomial infections

## **INTRODUCTION**

Microbes do manifest themselves in three ways, through substance spoilage, fermentation of organic and inorganic matters and causation of ailments. Different microorganisms, with their different mode of aetiology, causing different types of ailments, will require different methods

36 and capable drugs for treatments. Continuous deployment of antimicrobial drugs in treating  
37 microbial infections has led to the emergence of resistance amongst various strains of  
38 microorganisms [1, 2]. **Multi-drug resistance** (MDR) literally means ‘being resistant to more than  
39 one antimicrobial agent’, although a standardized definition has not yet been agreed upon by the  
40 medical community. There are currently other definitions that are used to characterize patterns  
41 multidrug resistance. The most practical definition used for Gram-positive and Gram-negative  
42 bacteria is ‘resistance to three or more antimicrobial classes according to Magiorakos *et al.* [3].  
43 MDR could also be defined as the insensitivity or resistance of a microorganism to administered  
44 antimicrobial medicines (which are structurally unrelated and have different molecular targets)  
45 despite earlier sensitivity to the same medicines [4].

46 According to Nikaido [5], multidrug resistance in bacteria cells come about by their  
47 accumulation, on resistance (R) plasmids or transposons, of genes, with each coding for  
48 resistance to a specific agent, and/or by the action of multidrug efflux pumps, each of which can  
49 pump out more than one drug type. This MDR abilities lead to ineffective ailment treatment,  
50 resulting in its persistence, infection’s spread and high cost [2, 6].

51 The hospital environment have been said to be **an** active reservoir for infectious microorganisms,  
52 being the meeting point for people with diverse disease etiological agents and susceptible  
53 individuals [7, 8, 9]. Nikaido [5] mentioned that *Staphylococcus aureus* has a known  
54 nosocomial, multi-drug-resistant strain referred to as the methicillin-resistant *Staphylococcus*  
55 *aureus* (MRSA). MRSA was initially controlled but currently is also resistant to other  
56 antimicrobials like the aminoglycosides, chloramphenicol, lincosamides, macrolides and  
57 tetracycline [1]. This study was conducted as part of evidence to buttress the efficacy of  
58 *Staphylococcal* infections in young children and the scale to which MDR pathogens are  
59 becoming threats to the health of the younger generation amongst the Mkpato Enin, Akwa-Ibom  
60 State populace.

61

## 62 **MATERIALS AND METHODS**

### 63 **Study Facility, Group and Sample Collection**

64 The study facility is in a growing town and services a couple of adjoining communities, with a  
65 number of established institutions, stable commerce and ever growing population. The General

66 Hospital, Ikot-Ekpaw, in Mkpato Enin LGA, Akwa-Ibom State, South-South Nigeria, has Out-  
67 patient department, Post-natal ward, Paediatric ward and servicing laboratories. The study  
68 focused on children aged 1-15 years.

69 A hundred (100) sterile swabs samples from skin, nostrils, wound, throat and ear was sourced  
70 over a period of three months. Once gotten, the swabs were labelled, placed in an ice pack and  
71 taken to the Microbiology laboratory, Akwa-Ibom State University.

## 72 **Sample Analysis**

73 The sterile swab sticks were **dipped** into peptone water and incubated at 37°C for 24 hours. A  
74 loopful from each sample was streaked on separate Mannitol salt agar (MSA) plates and  
75 incubated at 37°C for 24 hours. Discrete golden yellow colonies were subcultured, purified and  
76 preserved. Only Gram positive cocci bacterial colonies were further tested for catalase and  
77 coagulase.

## 78 **Antibiotics Susceptibility Test**

79 Confirmed *Staphylococcus aureus* isolates were tested for their susceptibilities to various  
80 selected commercial antibiotic drugs like Ciprofloxacin, Erythromycin, Levofloxacin,  
81 Gentamicin, Ampiclox, Rifampicin, Amoxicillin, Streptomycin, Norfloxacin and  
82 Chloramphenicol. Overnight cultures using Kirby-Bauer method [10] were inoculated on  
83 Mueller-Hinton agar (Oxoid, Uk), cultures adjusted to 0.5 McFarland standard. After pre-  
84 diffusion, the plates were **incubated** at 37°C for 24 hours. Diameter of zones of inhibition (IZDs)  
85 produced by the antibiotics were measured and recorded in millimeter. Thereafter, the Multiple  
86 antibiotics resistance (MAR) index was **determined** for each isolate using a formula  $MAR = x/y$ ,  
87 where  $x$  is the number of antibiotics to which test isolate displayed resistance and  $y$  is the total  
88 number of antibiotics to which the test organism has been evaluated for sensitivity [11, 12].

89

## 90 **RESULTS AND DISCUSSIONS**

91 Result for the prevalence of *S. aureus* is as shown in Table 1. The result table shows that of the  
92 28 confirmed, wound samples had the highest number, which was followed by samples from  
93 children skin swabs. The least number of confirmed *Staphylococcus aureus* isolates were from  
94 the ear swabs.

95 The susceptibility pattern of the 28 confirmed test isolates to the selected commercially available  
96 drugs (amoxicillin, ampiclox, chloramphenicol, ciprofloxacin, erythromycin, gentamicin,

97 levofloxacin, norfloxacin, rifampicin and streptomycin) is as shown in Figure 1. Ciprofloxacin  
 98 was the most effective drugs against the test organism, followed by Levofloxacin and  
 99 Norfloxacin. Confirmed *Staphylococcus aureus* isolates had high resistance for Amoxicillin,  
 100 closely followed by their resistance for Ampiclox.


101

102

**Table 1: Prevalence of *Staphylococcus aureus* from clinical samples**

Type of Specimen	Sample Size	Number of <i>S. aureus</i> isolated	Total percentage
Skin	20	8	29
Nose	20	5	18
Wound	20	9	32
Throat	20	4	14
Ear	20	2	7

103



**Figure 1: Antibiotics susceptibility pattern of *Staphylococcus* strains from clinical sample**

104

105 **KEY:** R= Resistant, S= Sensitive, CPX= Ciprofloxacin, E= Erythromycin, LEV= Levofloxacin, CN= Gentamicin,  
 106 APX= Ampiclox, RD= Rifampicin, AMX= Amoxicillin, S= Streptomycin, NB= Norfloxacin, CH=  
 107 Chloramphenicol  
 108

109 Table 2 has the multiple antibiotics resistance (MAR) index result which shows that 85.7% of the  
 110 confirmed test isolates were multi-drug resistant (showing resistance to three or more classes of  
 111 antibiotics). Only 14.3% of the isolates showed resistance to only two classes of antibiotics.  
 112 Results from this study show that 60.7% of test isolates had resistance for four or more  
 113 antibiotics drugs. MAR index value for 96.4% of the test isolates reveal cases of source drug  
 114 abuse.

**Table 2: Antibiotic Resistance Pattern and MAR index of *Staphylococcus aureus***

S/N	ISOLATE CODE	Antibiotic Resistant Pattern	MARI	Antibiotic Resistant Class
1	S9	RD, S	0.2	RIF, AMG
2	S8	APX, AMX, CH	0.3	PEN, CHL
3	N3	LEV, APX, AMX	0.3	QUI, PEN
4	W1	CN, AMX, CH	0.3	AMG, PEN, CHL
5	W9	APX, AMX, S	0.3	PEN, AMG
6	S10	CN, APX, RD, AMX	0.4	AMG, PEN, RIF
7	T6	E, APX, AMX, NB	0.4	MAC, PEN, QUI
8	T8	CPX, E, APX, AMX	0.4	QUI, MAC, PEN
9	S2	E, APX, RD, AMX, S	0.5	MAC, PEN, RIF, AMG
10	S3	E, CN, APX, AMX, S	0.5	MAC, AMG, PEN
11	N1	E, CN, APX, AMX, CH	0.5	MAC, AMG, PEN, CHL
12	N2	CN, APX, AMX, S, CH	0.5	AMG, PEN, CHL
13	W2	E, LEV, APX, AMX, S	0.5	MAC, QUI, PEN, AMG
14	W5	E, APX, AMX, S, CH	0.5	MAC, PEN, AMG, CHL
15	W6	CN, APX, AMX, S, CH	0.5	AMG, PEN, CHL
16	W7	APX, AMX, S, NB, CH	0.5	PEN, AMG, QUI, CHL
17	W10	E, LEV, APX, AMX, S	0.5	MAC, QUI, PEN, AMG
18	T3	E, APX, AMX, S, CH	0.5	MAC, PEN, AMG, CHL
19	E5	E, CN, APX, RD, AMX	0.5	MAC, AMG, PEN, RIF
20	S1	E, CN, APX, RD, AMX, S	0.6	MAC, AMG, PEN, RIF
21	S5	E, LEV, APX, RD, AMX, S	0.6	MAC, QUI, PEN, RIF, AMG
22	S6	CN, APX, RD, AMX, S, CH	0.6	AMG, PEN, RIF, CHL
23	N5	CPX, CN, APX, AMX, S, CH	0.6	QUI, AMG, PEN, CHL

24	W8	E, CN, APX, AMX, S, NB	0.6	MAC, AMG, PEN, QUI
25	N8	E, CN, APX, RD, AMX, S, NB	0.7	MAC, AMG, PEN, RIF, QUI
26	W3	LEV, CN, APX, RD, AMX, S, NB	0.7	QUI, AMG, PEN, RIF
27	T2	E, CN, APX, RD, AMX, S, CH	0.7	MAC, AMG, PEN, RIF, CHL
28	E9	CPX, E, CN, APX, AMX, S, CH	0.7	QUI, MAC, AMG, PEN, CHL

**KEY:** CPX= Ciprofloxacin, E= Erythromycin, LEV= Levofloxacin, CN= Gentamicin, APX= Ampiclox, RD= Rifampicin, AMX= Amoxicillin, S= Streptomycin, NB= Norfloxacin, CH= Chloramphenicol, MARI= Multiple antibiotic resistance index, RIF= Rifamycins, AMG= Aminoglycosides, PEN= Penicillins, CHL= Chloramphenicol, MAC= Macrolides, QUI= Quinolones

115 Data for isolate occurrence and confirmation showed that there were more confirmed  
 116 *Staphylococcus* isolates from wound swab-samples, followed by skin swab-samples. Parta *et al.*  
 117 [13] also recorded very high *Staphylococcus* number from wound swabs. This high isolate-  
 118 numericals is suggestive of the exposed nature of the sampling points. This is supported by  
 119 findings presented by Nimmo *et al.* [14], who found more *Staphylococcus* isolates on exposed  
 120 body surfaces than the internal parts. While uncovered wounds have sticky surfaces and the skin  
 121 is continuously exposed, it is therefore easy for such high microbial numbers to be recorded.

122 Susceptibility data showed that all the confirmed and tested isolates resisted two or more  
 123 antimicrobials. Qureshi *et al.* [15] also isolated MRSA that resisted multiple anti-microbials from  
 124 hospital specimens. This study's result showed a higher MDR percentage than the "nearly half"  
 125 proportion reported by Nimmo *et al.* [14].

126 More than 96.4% of the MAR indices were 0.3 from this study evaluation. This assertion is  
 127 indicative that resistance to these multiple drugs come from over exposure of the isolates to  
 128 drugs, making them adapt or resistant to them with recurrent treatments. The high case of MDR  
 129 amongst microorganisms can drastically be reduced by mere restricting the indiscriminate and  
 130 readily availability of these drugs over the counter [14].

131

## 132 CONCLUSION

133 **In conclusion**, many studies have shown that prolonged stays in hospitals increases the risk for  
 134 **the** colonization or infection with MDR *Staphylococcus aureus*. This reflects an inherent risk in  
 135 acquiring MDR organisms through environmental contaminations and hospital stay conditions.  
 136 With infant patients, another potential transmission route is through infected staff members  
 137 handling and this calls for special care [16, 17].

138

139 The isolation of MDR *Staphylococcus aureus* from infant patients is a call for the proper  
140 implementation of contact precautions during hospitalization especially in health facilities across  
141 developing countries [16, 18].

#### 142 **Ethical consideration**

143 The study was approved by the ministry of health, Akwa Ibom State. Permission was obtained  
144 from General Administration of the General hospital prior to collecting any data. Participants'  
145 privacy and confidentiality have been assured (no names have been used, only numbers were  
146 used) and all data and results have been handled and treated confidentially.  
147

#### 148 **REFERENCES**

149 1 McIntosh, J. (2018). Antibiotic resistance: What you need to know. Medical news today,  
150 (<https://www.medicalnewstoday.com/articles/283963.php>).

151 2 Tanwar, J., Das, S., Zeeshan, F. and Hameed, S. (2014). Multidrug Resistance: An Emerging  
152 Crisis. *Interdisciplinary Perspectives on Infectious Diseases*, 7 pages.

153 3 Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G.,  
154 Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D. L., Rice, I. B.,  
155 Stelling, J., Struelens, M. J., Vatopoulos, A., Weber J. T. and Monnet, D. L. (2012). Multidrug-  
156 resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert  
157 proposal for interim standard definitions for acquired resistance. *Clinical Microbiology and*  
158 *Infection*, 18, 268–281.

159 4 Singh, V. (2013). Antimicrobial resistance *In: Microbial Pathogens and Strategies for*  
160 *Combating Them: Science, Technology and Education*, Formatex Research Center, 1, 291-296.

161 5 Nikaido, H. (2009). Multidrug Resistance in Bacteria. *Annual Review of Biochemistry*, 78,  
162 119–146.

163 6 WHO (2014). *Antimicrobial Resistance Global Report on Surveillance*. Geneva, Switzerland:  
164 World Health Organization.

165 7 Zhanel, G. G., DeCorby, M., Laing, N., Weshnoweski, B., Vashisht, R., Tailor, F., Nichol, K.  
166 A., Wierzbowski, A., Baudry, P. J., Karlowsky, J. A., Lagacé-Wiens, P., Walkty, A.,  
167 McCracken, M., Mulvey, M. R. and Johnson, J. (2008). The Canadian Antimicrobial Resistance  
168 Alliance (CARA), and Hoban DJ (2008). Antimicrobial-resistant pathogens in intensive care  
169 units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-  
170 2006. *Antimicrobial Agents and Chemotherapy*, 52, 1430-1437.

171 8 Rhomberg, P. R., Fristoche, T. R., Sader, H. S. and Jones, R. N. (2006). Antimicrobial  
172 susceptibility pattern comparisons among intensive care unit and general ward Gram negative  
173 isolates from meropenem yearly susceptibility test Information programme (USA). *Diagnostic*  
174 *Microbial Infectious Disease*, 56, 57-62.

- 175 9 O'Brien, F. G., Pearman, J. W., Gracey, M., Riley, T. V. and Grubb, W. B. (1999). Community  
176 strain of methicillin-resistant *Staphylococcus aureus* involved in a hospital outbreak. *Journal of*  
177 *Clinical Microbiology*, 37(9):2858–2862.
- 178 10 Hudzicki, J. (2009). Kirby-Bauer disk diffusion susceptibility test protocol. *American Society*  
179 *for Microbiology*, 23 pages.
- 180 11 Tula-Sanchez, A. A., Havas, A. P., Alonge, P. J., Klein, M. E., Doctor, S. R., Pinkston, W.,  
181 Glinsmann-Gibson, B. J., Rimsza, L. M. and Smith, C. (2013). A model of sensitivity and  
182 resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-  
183 dependent kinase inhibitors. *Cancer Biology and Therapy*, 14(10): 949-961.
- 184 12 Olayinka, A. T., Onile, B. A. and Olayinka, B. O. (2004). Prevalence of multi-drug resistance  
185 (MDR) *Pseudomonas aeruginosa* isolates in surgical units of Ahmadu Bello University  
186 Teaching Hospital, Zaria, Nigeria: An indication for effective control measures. *Annals of*  
187 *African Medicine*, 3(1): 13-16.
- 188 13 Parta, M., Goebel, M., Matloobi, M., Stager, C. and Musher, D. M. (2009). Identification of  
189 Methicillin-Resistant or Methicillin-Susceptible *Staphylococcus aureus* in Blood Cultures  
190 and Wound Swabs by GeneXpert. *Journal of Clinical Microbiology*, 47(5):1609–1610.
- 191 14 Nimmo, G. R., Pearson, J. C., Collignon, P. J., Christiansen, K. J., Coombs, G. W., Bell, J.  
192 M., McLaws M. L. and the Australian Group on Antimicrobial Resistance (2011).  
193 Antimicrobial susceptibility of *Staphylococcus aureus* isolated from hospital in-patient.  
194 *Community Disease Intelligence*, 35(3):237–243.
- 195 15 Qureshi, A. H., Rafi, S., Qureshi, S. M. and Ali, A. M. (2004). The Current Susceptibility  
196 Patterns of Methicillin Resistant *Staphylococcus aureus* to Conventional Anti-*Staphylococcus*  
197 Antimicrobials at Rawalpindi. *Pakistan Journal of Medical Science*, 20(4): 361-364.
- 198 16 Buke, C., Armand-Lefevre, L., Lolom, I., Guerinot, W., Deblangy, C., Ruimy, R.,  
199 Andremont, A. and Lucet J. C. (2007). Epidemiology of multidrug-resistant bacteria in patients  
200 with long hospital stays. *Infection Control and Hospital Epidemiology*, 28(11):1255–1260.
- 201 17 Maamar, E., Ferjani, S., Jendoubi, A., Hammami, S., Hamzaoui, Z., Mayonnove-Coulange,  
202 L., Saidani, M., Kammoun, A., Rehaïem, A., Ghedira, S., Houissa, M., Boutiba-Ben Boubaker,  
203 I., Slim, A. and Dubois, V. (2016). High prevalence of gut microbiota colonization with broad-  
204 spectrum cephalosporin resistant enterobacteriaceae in a tunisian intensive care unit. *Frontiers in*  
205 *Microbiology*, 7, 1859.
- 206
- 207 18 Harbarth, S., Sax, H., Fankhauser-Rodriguez, C., Schrenzel, J., Agostinho, A. and Pittet, D.  
208 (2006). Evaluating the probability of previously unknown carriage of MRSA at hospital  
209 admission. *American Journal of Medicine* 119(3):275.e15-e23